Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...
Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are ...
CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed what they called “alarming” underutilization of disease-modifying therapies for sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results